Unknown

Dataset Information

0

Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.


ABSTRACT: In trials designed to evaluate new therapies for hematologic malignancies, end points such as leukemia-free survival are often used as surrogates for overall survival in acute leukemia. We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied to remission maintenance therapy for acute myeloid leukemia.Data were analyzed from a randomized Phase III trial of remission maintenance immunotherapy with histamine dihydrochloride plus low-dose interleukin-2 versus no treatment in adults with acute myeloid leukemia. A two-stage surrogate validation model was applied in which correlations between Kaplan-Meier estimates of leukemia-free survival and overall survival, and between log hazard ratios reflecting treatment effects were analyzed. Country of patient enrollment was the unit of analysis.Kaplan-Meier estimates of overall survival at 36, 48, and 60 months and leukemia-free survival at 24 months were reasonably correlated (R(2) ranging from 0.44 to 0.84) both for the overall (n=320) and first complete remission (n=261) populations. The effects of histamine dihydrochloride/interleukin-2 on log hazard ratios for leukemia-free survival and overall survival were well correlated (R(2)=0.88-0.93).The significant correlations between overall survival and the surrogate end point (leukemia-free survival) and between the effect of histamine dihydrochloride/interleukin-2 on leukemia-free survival and overall survival satisfy the two-stage surrogate validation model.

SUBMITTER: Buyse M 

PROVIDER: S-EPMC3148903 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.

Buyse Marc M   Michiels Stefan S   Squifflet Pierre P   Lucchesi Kathryn J KJ   Hellstrand Kristoffer K   Brune Mats L ML   Castaigne Sylvie S   Rowe Jacob M JM  

Haematologica 20110505 8


<h4>Background</h4>In trials designed to evaluate new therapies for hematologic malignancies, end points such as leukemia-free survival are often used as surrogates for overall survival in acute leukemia. We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied to remission maintenance therapy for acute myeloid leukemia.<h4>Design and methods</h4>Data were analyzed from a randomized Phase III trial of remission maintenance immunot  ...[more]

Similar Datasets

| S-EPMC5559931 | biostudies-other
| S-EPMC9514834 | biostudies-literature
| S-EPMC5546120 | biostudies-other
| S-EPMC6560345 | biostudies-literature
| S-EPMC6991254 | biostudies-literature
| S-EPMC8647999 | biostudies-literature
| S-EPMC6593671 | biostudies-literature
| S-EPMC5445001 | biostudies-literature
| S-EPMC7289793 | biostudies-literature
| S-EPMC6423478 | biostudies-literature